Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies

Categories: Hi-Tech

Plaintiffs, in the US, filed a total of 43 securities class action lawsuits against life sciences companies in 2022, which represented almost one in four securities class action lawsuits.

A Dechert survey, for any Israeli life sciences companies with a US presence, identifying various trends relating to the origin of such suits, including issues stemming from misrepresentations regarding efficacy and safety, sufficiency of FDA applications, and unlawful conduct.

Click here to read the survey.

Dechert LLP